## Luis Lara-MejÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1485925/publications.pdf

Version: 2024-02-01

1684188 1474206 12 81 5 9 citations g-index h-index papers 12 12 12 130 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID $\hat{a}$ 49 pandemic: the THOCOoP cooperative group. Critical Reviews in Oncology/Hematology, 2020, 153, 103033.	4.4	17
2	Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Lung Cancer, 2021, 152, 119-126.	2.0	17
3	Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer, 2020, 20, 829.	2.6	11
4	Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. Lung Cancer, 2021, 155, 183-190.	2.0	8
5	Clinical Impact of the COVID â€19 Pandemic in Mexican Patients with Thoracic Malignancies. Oncologist, 2021, 26, 1035-1043.	3.7	6
6	Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 510-522.	2.6	5
7	Brigatinib in <i>ALK</i> -positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). Future Oncology, 2021, 17, 169-181.	2.4	5
8	Carboplatin plus etoposide or topotecan for small-cell lung cancer. Lancet Oncology, The, 2020, 21, 1132-1134.	10.7	4
9	RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer, 2021, 21, 892.	2.6	3
10	Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Pathology and Oncology Research, 2021, 27, 597499.	1.9	2
11	Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. Cancer Biomarkers, 2021, 32, 1-13.	1.7	2
12	Locoregional control and toxicity after pleurectomy/decortication and <scp>intensityâ€modulated</scp> pleural radiation therapy in patients with malignant pleural mesothelioma. Thoracic Cancer, 2020, 11, 3448-3455.	1.9	1